Sativex Reduces MS-Related Spasticity

Delta-9-Tetrahydrocannabidiol Oromucosal Spray (Sativex): A Review in Multiple Sclerosis-Related Spasticity

A debilitating symptom of multiple sclerosis (MS) is spasticity, the stiffness and involuntary spasms of muscles, often occurring in the legs. In a randomized study involving MS patients who have not experienced relief with any current anti-spasticity medication, Sativex, a THC/CBD oro-mucosal spray was administered. Patients receiving THC/CBD experienced significantly more spasticity relief than the placebo group. Sativex may hold substantial treatment potential for MS patients, as side effects are minimized, the spray allows for an adjustable dosage, and there is low potential for abuse.

While this pharmaceutical is proving to be effective, in related data, we also see a distinct advantage of non-pharmaceutical options, including cost, availability, and efficacy, although drastically higher variability and limited consistency in product.

Benjamin Caplan, MDSativex Reduces MS-Related Spasticity

Related Posts